drugset / Trial / NCT00850681

A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

NCT00850681

Phase 1 Completed 50 enrolled Peplin
NaSingle-groupOpen-labelTreatment

Summary

This Phase 1 study is designed to determine the photoallergic potential of PEP005 Gel, 0.01% and it's vehicle on normal skin.

Timeline

Start
2009-02
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject ingenol mebutate Small molecule 0.01 % Topical

Indications